PULMONARY EMBOLISM and Thyroid

PatientsVille

Find and Compare Side Effects

PULMONARY EMBOLISM Symptoms and Causes

A pulmonaryembolism is a sudden blockage in a lung artery. The cause is usually a blood clot in the leg called a deep vein thrombosis that breaks loose and travels through the bloodstream to the lung. Pulmonaryembolism is a serious condition that can cause

Permanent damage to the affected lung

Low oxygen levels in your blood

Damage to other organs in your body from not getting enough oxygen

If a clot is large, or if there are many clots, pulmonaryembolism can cause death.

Half the people who have pulmonaryembolism have no symptoms. If you do have symptoms, they can include shortness of breath, chest pain or coughing up blood. Symptoms of a blood clot include warmth, swelling, pain, tenderness and redness of the leg. The goal of treatment is to break up clots and help keep other clots from forming.

PULMONARY EMBOLISM Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.

proportion of patients in each treatment arm euthyroid through gestation; the proportion of patients in each arm who required, and the gestation week at which, levothyroxine dose adjustments (either increased or decreased) occurred to maintain a euthyroid state; Determination of the necessary frequency of serum evaluation of TSH during the first half of gestation.

The proportion of patients that do not need a change of dose.; The magnitude of the change in daily dose needed.; Proportion of patients that obtained a thyroid stimulating hormone between 0.4-2.5 mU/L; Change from baseline serum thyroid stimulating hormone (in mIU/L and percentage).

Effect of the treatment of subclinical hypothyroidism on the apnea hypopnea index (AHI) score.; Effect of the treatment of subclinical hypothyroidism on the lipid profile in patient with dyslipidemia and on hs-CRP

Remission rate as defined by patients who are biochemically euthyroid at the end of the 6 year study period.; Biochemical control as reflected by blood TSH and thyroxine levels; The frequency of adverse events on the 2 treatment regimens.

Change in TSH (thyrotropin-stimulating-hormone) with each beverage type; Change in TSH with various beverages; Change in total T4 with each beverage type; Change in free T4 with each beverage type; Change in total T3 with each beverage type

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly.
PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.